Related Experiment Videos

Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with

M Hamada1, Y Shigematsu, Y Hara

  • 1The Second Department of Internal Medicine, Ehime University School of Medicine, Onsen-gun, Japan.

Japanese Circulation Journal
|June 16, 2001
PubMed

Insights

Cibenzoline improves diastolic function in hypertrophic cardiomyopathy (HCM) patients by enhancing E-wave velocity and reducing A-wave velocity. While it suppresses systolic function, its direct action markedly improves left ventricular diastolic dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Research

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex heart condition affecting left ventricular function.
  • Diastolic dysfunction is a key feature of HCM, impacting cardiac filling and relaxation.
  • Understanding drug effects on HCM is crucial for patient management.

Purpose of the Study:

  • To investigate the effects of cibenzoline on left ventricular diastolic function in patients with hypertrophic cardiomyopathy (HCM).
  • To assess changes in systolic and diastolic parameters following oral administration of cibenzoline.

Main Methods:

  • Echocardiography, apexcardiography, and gated radionuclide angiography were used.
  • Measurements were taken before and 2 hours after oral administration of 200 mg cibenzoline.
  • The study included patients with hypertrophic obstructive cardiomyopathy (HOCM) and hypertrophic nonobstructive cardiomyopathy (HNCM).

Main Results:

  • Cibenzoline significantly reduced the left ventricular pressure gradient in HOCM patients.
  • Fractional shortening decreased, indicating suppressed systolic function in both HOCM and HNCM groups.
  • E-wave velocity increased, A-wave velocity decreased, and filling times shortened, demonstrating improved diastolic function.

Conclusions:

  • Cibenzoline demonstrates a dual effect in HCM patients: suppressing systolic function while significantly improving left ventricular diastolic dysfunction.
  • The drug's direct action appears to be beneficial for diastolic abnormalities in HCM.
  • Further research may explore cibenzoline's therapeutic potential in managing HCM-related diastolic dysfunction.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...